在体外受精程序中短期使用促性腺激素释放激素激动剂（布舍瑞林）诱导排卵。

Short-term utilization of a gonadotropin-releasing hormone agonist (buserelin) for induction of ovulation in an in vitro fertilization program.

作者信息

Loumaye E, de Cooman S, Anoma M, Psalti I, Depreester S, Schmit M, Thomas K

机构信息

Department of Obstetrics and Gynecology, University of Louvain, Brussels, Belgium.

出版信息

Ann N Y Acad Sci. 1988;541:96-102. doi: 10.1111/j.1749-6632.1988.tb22245.x.

DOI:10.1111/j.1749-6632.1988.tb22245.x

PMID:3143299

Abstract

Benefits of the short-term utilization of a gonadotropin-releasing hormone (GnRH) agonist (Buserelin, Hoechst, AG, Frankfurt am Mein, FRG) for induction of ovulation in an in vitro fertilization program (IVF) program were assessed. Eighteen patients underwent consecutively an induction of ovulation by clomiphene citrate (CC) and human menopausal gonadotropin (hMG), then by hMG alone, and finally by Buserelin and hMG. The switchover from CC and hMG to hMG alone significantly increased the number of aspirated follicles and the oocyte recovery rate. The addition of Buserelin prevented the outcome of spontaneous luteinizing hormone (LH) surges. It reduced the preovulatory luteinization and increased the number of recovered oocytes as well as the number of embryos available for transfer. A 33% clinical pregnancy rate per ovum pick-up was achieved with the Buserelin-hMG treatment.

摘要

评估了在体外受精（IVF）程序中短期使用促性腺激素释放激素（GnRH）激动剂（布舍瑞林，赫斯特公司，德国美因河畔法兰克福）诱导排卵的益处。18名患者先后接受枸橼酸氯米芬（CC）和人绝经期促性腺激素（hMG）诱导排卵，然后单独使用hMG，最后使用布舍瑞林和hMG。从CC和hMG转换为单独使用hMG显著增加了抽吸卵泡的数量和卵母细胞回收率。添加布舍瑞林可防止自发促黄体生成素（LH）峰的出现。它减少了排卵前的黄素化，增加了回收的卵母细胞数量以及可用于移植的胚胎数量。布舍瑞林-hMG治疗的每次取卵临床妊娠率达到33%。